Notably, experimental studies have reported neuroprotective effects of selective COX-1 inhibition and NSAIDs, with higher selectivity for COX-1, in models of neurodegenerative diseases such as Alzheimer disease and traumatic brain injury (41–49). Here, PTGS1 is linked to neurodegenerative disease.